Further downside for Spark Therapeutics?

Yesterday, Spark Therapeutics, Inc (NASDAQ:ONCE) saw a 35% decline. This was due to an increased negative sentiment for the stock. At the American Society of Hematology’s (ASH) annual meeting, ONCE presented rather disappointing data on their trials of their experimental drug to treat Hemophilia-A. Spark’s data showed that though its